LIPO (Lipella Pharmaceuticals) ROE % Adjusted to Book Value: -127.51% (As of Sep. 2025)


What is Lipella Pharmaceuticals ROE % Adjusted to Book Value?

Lipella Pharmaceuticals LIPO ROE % Adjusted to Book Value is -127.51% as of Sep. 2025. The stock has 1 warning sign investors should review.

Lipella Pharmaceuticals's ROE % for the quarter that ended in Sep. 2025 was -237.16%. Lipella Pharmaceuticals's PB Ratio for the quarter that ended in Sep. 2025 was 1.86. Lipella Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 was -127.51%.

Lipella Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Lipella Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Lipella Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipella Pharmaceuticals ROE % Adjusted to Book Value Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
0.00 0.00 -22.18 -60.27 -103.20

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -129.60 -177.86 -111.03 -110.38 -127.51

LIPO vs WINT, RMTG, CYTOF: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Lipella Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipella Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Lipella Pharmaceuticals's ROE % Adjusted to Book Value falls into.


Lipella Pharmaceuticals ROE % Adjusted to Book Value Calculation

Lipella Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-198.14% / 1.92
=-103.20%

Lipella Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-237.16% / 1.86
=-127.51%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -127.51% mean?
Lipella Pharmaceuticals (LIPO) has a ROE % Adjusted to Book Value of -127.51% as of Sep. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Lipella Pharmaceuticals and its competitors.
Is Lipella Pharmaceuticals' ROE % Adjusted to Book Value too high?
Lipella Pharmaceuticals' current ROE % Adjusted to Book Value is -127.51%.
How does Lipella Pharmaceuticals' ROE % Adjusted to Book Value compare to WINT and RMTG?
Lipella Pharmaceuticals' ROE % Adjusted to Book Value of -127.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current ROE % Adjusted to Book Value is -127.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.67, compared to a current price of $0.09 — trading 99% below its estimated fair value. The current ROE % Adjusted to Book Value is -127.51%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current ROE % Adjusted to Book Value is -127.51% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lipella Pharmaceuticals Business Description

Address 7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.